Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29521322 | 1.00 | ALDH1A1 (0.32) | ALDH1A1MEN1PSMD14LMNAKMT2A | |
| SCHEMBL20465926 | 0.89 | ALDH1A1 (0.32) | ALDH1A1MEN1PSMD14LMNAKMT2A | |
| SCHEMBL29521552 | 0.89 | L3MBTL1 (0.36) | ALDH1A1MEN1PSMD14LMNAKMT2A | |
| SCHEMBL20455822 | 0.89 | L3MBTL1 (0.36) | ALDH1A1MEN1PSMD14LMNAKMT2A | |
| SCHEMBL29521456 | 0.87 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1PKM | |
| SCHEMBL20468387 | 0.87 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1PKM | |
| SCHEMBL29521430 | 0.85 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL20468388 | 0.85 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL29521336 | 0.85 | L3MBTL1 (0.33) | ALDH1A1MEN1LMNAKMT2AL3MBTL1 | |
| SCHEMBL20455823 | 0.85 | L3MBTL1 (0.33) | ALDH1A1MEN1LMNAKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110248942-B | Process for preparing halogenated imidazopyridine derivatives | 拜耳公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3577114-B1 | METHOD FOR THE PREPARATION OF HALOGENATED IMIDAZOPYRIDINE DERIVATIVES | BAYER AG (DE) | 2021-11-10 | — | — | EP | disclosed |
| US-11072609-B2 | Method for preparing halogenated imidazopyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-07-27 | — | — | US | disclosed |
| US-11072609-B2 | Method for preparing halogenated imidazopyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20210094947-A1 | METHOD FOR PREPARING HALOGENATED IMIDAZOPYRIDINE DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2021-04-01 | — | — | US | disclosed |
| US-20210094947-A1 | METHOD FOR PREPARING HALOGENATED IMIDAZOPYRIDINE DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2021-04-01 | — | — | US | disclosed |
| WO-2018141955-A1 | PROCESS FOR PREPARING HALOGENATED IMIDAZOPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094947-A1 | METHOD FOR PREPARING HALOGENATED IMIDAZOPYRIDINE DERIVATIVES | CYP2F1, CYP2D6, POLR2A | ALDH1A1 853/4885MEN1 1024/4885PSMD14 3841/4885 |
| US-11072609-B2 | Method for preparing halogenated imidazopyridine derivatives | CYP2F1, CYP2D6, POLR2A | ALDH1A1 853/4885MEN1 1024/4885PSMD14 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.